FLINT, Mich. — Diplomat on Thursday announced availability of a new top-line treatment for metastatic breast cancer. The specialty pharmacy will dispense Kisqali, which was recently approved by the Food and Drug Administration.
Kisqali is a once-daily oral therapy for postmenopausal women with advanced of metastatic breast cancer that’s hormone-receptor positive and negative for human epidermal growth factor receptor 2. It’s meant to be used in combination with an aromatase inhibitor.
“The diagnosis of advanced or metastatic breast cancer has a devastating impact on patients, as well as their loved ones,” Diplomat president Paul Urick said. “Kisqali is a groundbreaking new treatment that can improve quality of life for our patients.”